Table 2.
Lyme disease tests at large commercial laboratories by type and percent positive, in four states, 20081
| No. of Tests | % of Tests | % Positive2 | |
|---|---|---|---|
| 701,006 | 68 | 5.8 | |
| Two-Tiered Whole Cell ELISA/EIA or C6 ELISA3 | |||
| Standalone Tests | |||
| IgG Western blot | 155,800 | 15 | 6.5 |
| IgM Western blot | 155,584 | 15 | 10.5 |
| IgM/IgG Combination | 82 | <1 | - |
| Whole Cell ELISA/EIA | 3,616 | <1 | 11.4 |
| C6 peptide ELISA | 1,655 | <1 | - |
| PCR4 | 7,637 | <1 | 3.1 |
| CSF Antibody5 | 3,055 | <1 | - |
| Culture | 7 | <1 | 0 |
|
| |||
| Total | 1,053,445 | ||
1
Data aggregated from seven U.S. commercial laboratories. Includes specimen testing data from providers in Connecticut, Maryland, Minnesota, and New York.
2
Phase 1 %positive results are presented from five laboratories. CSF antibody not performed by these laboratories.
3
Positive results for C6 (standalone) not reported.
4
PCR testing of blood, cerebrospinal fluid, and/or synovial fluid.
5
No urine antigen tests were reported for these four states.